Main description:

The introduction of anti-vascular endothelial growth factor (VEGF) agents has revolutionized therapy for a host of ocular diseases associated with leakage from normal blood vessels and pathologic blood vessel growth. Anti-VEGF Use in Ophthalmology is an all-inclusive reference designed to provide detailed, up-to-date, and clinically relevant information on the current use of anti-VEGF agents in the treatment of all ocular conditions.

Drs. Jay S. Duker and Michelle C. Liang have assembled a prestigious group of contributors who pool their collective expertise in this comprehensive book. Anti-VEGF Use in Ophthalmology is split into two sections with the first providing the history of VEGF and an overview of anti-VEGF agents and different routes of drug delivery, as it is important for eye care providers to be familiar with up-to-date aspects of the medications and indications for use.

The second section details the clinical uses of anti-VEGF agents in numerous ocular diseases, from the anterior segment including cornea and glaucoma to uveitis and various retinal and choroidal diseases. Each chapter in this section summarizes the disease process and utilizes high-quality ocular imaging to demonstrate the therapeutic use of the anti-VEGF agents.

Some of the topics covered in Anti-VEGF Use in Ophthalmology:

Neovascular Age-Related Macular Degeneration
Proliferative Diabetic Retinopathy
Retinal Vein Occlusion
Uveitis
Neovascular Glaucoma
Macular Edema
Retinopathy of Prematurity
Corneal Disease
Anti-VEGF Use in Ophthalmology combines the theory and applications of anti-VEGF agents, making it not only a great learning tool for beginners but also a useful reference tool for a wide range of eye care professionals including optometrists, residents, comprehensive ophthalmologists, as well as specialists in anterior segment, pediatrics, and vitreoretinal disease.

Contents:

Dedication

About the Editors

Contributing Authors

Introduction

Section I Overview of Anti-Vascular Endothelial
Growth Factor Agents

Chapter 1 Vascular Endothelial Growth Factor:
Background and History

Anthony Joseph, MD and Ehsan Rahimy, MD

Chapter 2 Development of Anti-Vascular Endothelial
Growth Factor Agents

Maya H. Maloney, MD and Sophie J. Bakri, MD

Chapter 3 Available Anti-Vascular Endothelial
Growth Factor Agents

Angeline Mariani Derham, MD and David M. Brown, MD, FACS

Chapter 4 Agents Under Study

Ehsan Rahimy, MD; Elham Rahimy, BS;
and Anthony Joseph, MD

Chapter 5 Intravitreal Delivery

Nora Muakkassa, MD; Kendra Klein, MD; and
Elias Reichel, MD

Chapter 6 Sustained Delivery Options Under Study

Michael N. Cohen, MD; Chirag P. Shah, MD, MPH; and
Jeffrey S. Heier, MD

Section II Use of Anti-Vascular Endothelial
Growth Factor Agents in Clinical Practice

Chapter 7 Neovascular Age-Related Macular Degeneration

Michael D. Lewen, MD and Andre J. Witkin, MD

Chapter 8 Choroidal Neovascularization,
Not Age-Related Macular Degeneration

Darin R. Goldman, MD

Chapter 9 Diabetic Macular Edema

Emily D. Cole, BS; Eduardo A. Novais MD; and
Nadia K. Waheed, MD, MPH

Chapter 10 Proliferative Diabetic Retinopathy

Sabin Dang, MD and Chirag P. Shah, MD, MPH

Chapter 11 Retinal Vein Occlusion

Shilpa Desai, MD and Caroline R. Baumal, MD

Chapter 12 Uveitis

Lana M. Rifkin, MD

Chapter 13 Retinopathy of Prematurity

Nikisha A. Kothari, MD and Audina M. Berrocal, MD

Chapter 14 Miscellaneous Retinal and Choroidal Diseases

Michael D. Tibbetts, MD

Chapter 15 Neovascular Glaucoma

Manik Goel, MD and Joel S. Schuman, MD, FACS

Chapter 16 Glaucoma Surgery

Jessica J. Moon, MD and Cynthia Mattox, MD

Chapter 17 Anterior Segment Diseases

Alessandro Abbouda, MD; Bijan Khaksari, BA; and
Pedram Hamrah, MD, FRCS

Financial Disclosures

Index